Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
Corresponding Author
Naga Chalasani M.D.
Indiana University School of Medicine, Indianapolis, IN
Indiana University School of Medicine, WD OPW 2005, 1001 W. 10th Street, Indianapolis; IN 46202===Search for more papers by this authorArthur Baluyut
Indiana University School of Medicine, Indianapolis, IN
Search for more papers by this authorGagan Sood
Gagan Sood and the UAB Liver Center, University of Alabama at Birmingham, Birmingham, AL
Search for more papers by this authorT. M. McCashland
University of Nebraska Medical Center, Omaha, NE
Search for more papers by this authorK. Rajender Reddy
University of Miami Medical Center, Miami, FL
Search for more papers by this authorXaralambos Zervos
University of Miami Medical Center, Miami, FL
Search for more papers by this authorHelena Hoen
Indiana University School of Medicine, Indianapolis, IN
Search for more papers by this authorCorresponding Author
Naga Chalasani M.D.
Indiana University School of Medicine, Indianapolis, IN
Indiana University School of Medicine, WD OPW 2005, 1001 W. 10th Street, Indianapolis; IN 46202===Search for more papers by this authorArthur Baluyut
Indiana University School of Medicine, Indianapolis, IN
Search for more papers by this authorGagan Sood
Gagan Sood and the UAB Liver Center, University of Alabama at Birmingham, Birmingham, AL
Search for more papers by this authorT. M. McCashland
University of Nebraska Medical Center, Omaha, NE
Search for more papers by this authorK. Rajender Reddy
University of Miami Medical Center, Miami, FL
Search for more papers by this authorXaralambos Zervos
University of Miami Medical Center, Miami, FL
Search for more papers by this authorHelena Hoen
Indiana University School of Medicine, Indianapolis, IN
Search for more papers by this authorAbstract
Patients with primary sclerosing cholangitis (PSC) have a significantly increased risk of developing cholangiocarcinoma (CCA). Risk factors for developing such a complication are not well defined. We conducted a multicenter, case-control study to determine the risk factors and possible predictors for CCA in patients with PSC. The demographic, clinical, and laboratory features of 26 PSC patients with CCA diagnosed over a 7-year period at eight academic centers were compared with 87 patients with PSC but no CCA (controls). There was no statistically significant difference in demographics, smoking, signs or symptoms or complications of PSC, indices of disease severity (Mayo Risk score or Child-Pugh score), frequency or duration or complications of inflammatory bowel disease (IBD), frequency of biliary surgery, or therapeutic endoscopy between the two groups. Alcohol consumption was significantly associated with CCA in patients with PSC (odds ratio: 2.95; 95% CI: 1.04-8.3). Serum carbohydrate antigen 19-9 (CA 19-9) was significantly higher in patients with CCA than those without (177 ± 89 and 61 ± 58 U/mL, respectively;P = .002). A serum CA 19-9 level > 100 U/mL had 75% sensitivity and 80% specificity in identifying PSC patients with CCA. In conclusion, alcohol consumption was a risk factor for having CCA in PSC patients. The indices of severity of liver disease were not associated with CCA in patients with PSC. Serum CA 19-9 appeared to have good ability to discriminate PSC patients with and without CCA.
References
- 1 Weisner RH, Gramlosch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430–436.MEDLINE
- 2 Wei YL, Detre KM, Everhart JE. The NIDDK Liver Transplant Database. Liver Transpl Surg 1997; 3: 10–22.MEDLINE
- 3 Lin HM, Kaufmann HM, McBride MA, Davies DB, Rosendale JD, Smith CM, Edwards EB, et al. Center-specific graft and patient survival rates: 1997 United Network for Organ Sharing (UNOS) report. JAMA 1998; 280: 1153–1160.MEDLINE
- 4 Abu-Elmagd KM, Malinchoc M, Dickson RE, Fung JJ, Murtaugh PA, Langworthy AL, Demetris AJ, et al. Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet 1993; 177: 335–344.MEDLINE
- 5 Ricci P, Therneau TM, Malinchoc M, Benson JT, Petz JT, Klintmalm GB, Crippin JS, et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology 1997; 25: 672–677.MEDLINE
- 6 Knechtle SJ, D'Alessandro AM, Harms BA, Pirsch JD, Belzer FO, Kalayoglu M. Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery 1995; 118: 615–620.MEDLINE
- 7 Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, Martin P, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225: 472–483.MEDLINE
- 8 Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielson A, Prytz H, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610–615.MEDLINE
- 9 Kornfled D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997; 32: 1042–1045.MEDLINE
- 10 Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100: 1710–1717.MEDLINE
- 11 Aadland E, Schrumpf E, Fausa O, Elgo K, Heilo A. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987; 22: 655–664.MEDLINE
- 12 Martin MF, Rossi RL, Nugent FW, Scholz FJ, Jenkins RL, Lewis WD, Gagner M, et al. Surgical aspects of sclerosing cholangitis. Ann Surg 1990; 212: 551–558.MEDLINE
- 13 Steiber AC, Marino IR, Iwatsuki S, Starzl TE. Cholangiocarcinoma in sclerosing cholangitis. Role of liver transplantation. Int Surg 1989; 74: 324–340.
- 14 Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213: 21–25.MEDLINE
- 15 Miros M, Kerlin P, Walker N, Harper J, Lynch S, Strong R. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut 1991; 32: 1369–1373.MEDLINE
- 16 Nashan B, Schlitt HJ, Tusch G, Oldhafer KJ, Ringe B, Wagner S, Pichlmayer R. Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology 1996; 23: 1105–1111.MEDLINE
- 17 Patients waiting for transplant. UNOS scientific registry. UNOS Bull 1997; 2: 9–10.
- 18 Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865–869.MEDLINE
- 19 Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: an analysis of the serological marker CA 19-9. Mayo Clin Proc 1993; 68: 874–879.MEDLINE
- 20 Fisher A, Thiese ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, et al. CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transp Surg 1995; 1: 94–98.
- 21 Olivera MA, McCashland TM, Ruby L, Rouillard S, Somberg K, Reddy R. Mayo risk score is not predictive of cholangiocarcinoma associated with primary sclerosing cholangitis [Abstract]. Gastroenterology 1998 114: 94–98.
- 22 Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for the bleeding varices. Br J Surg 1973; 60: 646–649.MEDLINE
- 23 Weisner RH. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: predicting outcomes with natural history models. Mayo Clin Proc 1998; 73: 575–588.MEDLINE
- 24 Kim WR, Poterucha JJ, Weisner RH, LaRusso NF, Lindor KD, Petz J, Therneau TM, et al. The relative role of Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999; 29: 1643–1648.MEDLINE
- 25 Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27: 311–316.MEDLINE
- 26 Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinmeister AR, Offord KP, Melton III LJ. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996; 110: 1496–1502.MEDLINE
- 27 Van Erpecum KJ, Smits SJHM, Van De Meeberg PC, Linn FHH, Wolfhagen FHJ, van Berge-Henegouwen GP, Algra A. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996; 110: 1503–1506.MEDLINE
- 28 Anonymous. Cigarette smoking among adults—United States, 1995. MMWR 1997; 46: 1217–1220.
- 29 Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404–1408.MEDLINE
- 30 Hakamada K, Sasaki M, Endoh M, Itoh T, Morita T, Konn M. Late development of bile duct cancer after sphincteroplasty: a ten to twenty year follow-up study. Surgery 1997; 121: 488–492.MEDLINE
- 31 Chijiiwa K, Ichimiya H, Kuroki S, Koga A, Nakayama F. Late development of cholangiocarcinoma after the treatment of hepatolithiasis. Surg Gynecol Obstet 1993; 177: 279–282.MEDLINE